DOC

Business profile & competitive position

Healthpeak Properties, Inc. (DOC) sits in the Real Estate sector, specifically the REIT - Healthcare Facilities industry. It is an S&P 500, self-administered UPREIT whose operating subsidiary, Healthpeak OP, owns, operates, and develops U.S. healthcare real estate. As of December 31, 2025, the portfolio held interests in 689 properties spanning outpatient medical buildings, hospitals, lab/life science buildings, and senior housing, with a handful of non-reportable loans, a preferred equity investment, and three other properties.

The outpatient segment is the largest, with 507 of those properties and 2025 segment Adjusted NOI of $795.8 million. Roughly 79% of the outpatient medical buildings sit on or adjacent to hospital campuses, about 96% are affiliated with hospital systems, and around 72% are triple-net leased by leased square feet. That lease structure means tenants bear many property-level costs, which can mute expense volatility but also caps Healthpeak’s operating upside. The lab segment contributed $567.4 million of segment Adjusted NOI in 2025 from 145 properties, roughly 89% triple-net leased and heavily concentrated in San Francisco (59%), Boston (22%), and San Diego (17%). The remaining 34 senior housing properties generated $176.7 million of segment Adjusted NOI.

The competitive signal from the financials, however, is mixed. A P/E of 57.3 and a net margin of 8.6% plus a ROE of 3.3% suggest the market is valuing the company at a steep premium relative to the earnings and equity returns it is currently producing. Those returns are not a sign of an aggressive operational moat in the traditional sense; rather, they imply the stock is priced more for portfolio scarcity, dividend yield appeal, and the defensive reputation of healthcare real estate than for near-term earnings power. The beta of 0.99 means the stock has moved almost in line with the broader market, not like a low-volatility, bond-proxy REIT.

Financial posture

Healthpeak’s balance-sheet valuation is dominated by that P/E ratio of 57.3, which stands far above what a typical industrials or consumer name would carry. That multiple reflects both a depressed earnings base and REIT investors’ willingness to pay for income-oriented assets. With a net margin of 8.6%, the company is retaining only a small slice of revenue as accounting profit after expenses, depreciation, and interest. More importantly, ROE is just 3.3%, meaning shareholders are receiving a modest return on their equity claim after removing liabilities. In a sector where funds from operations (FFO) and net asset value (NAV) often matter more than GAAP EPS, those figures still indicate that reported earnings are not large relative to the equity base.

The current snapshot shows the stock at $20.07, below its 50-day EMA of $20.74, and an RSI of 37.8 — near the lower end of neutral and approaching oversold territory. A beta close to 1.00 tells traders they should not expect the shares to be an isolated safe-haven position; they tend to participate in broader market direction. Combine this with a $13.8 billion market cap, and Healthpeak is a large, liquid healthcare-lab hybrid REIT whose near-term price action will likely be driven by interest-rate expectations, its capital-markets event calendar, and quarterly funds-flow commentary more than by dramatic earnings beats.

Strategic priorities & outlook

Healthpeak’s most recent 10-K frames four operational priorities that matter for anyone following the stock.

• Portfolio composition and organic growth. The company plans to own, operate, and develop high-quality outpatient medical, lab, and senior housing real estate while managing the portfolio for long-term risk-adjusted returns and dividend growth.
• Balance-sheet discipline. Management targets an investment-grade balance sheet with ample liquidity and primarily long-term fixed-rate debt with staggered maturities to limit interest-rate and refinancing risk.
• Tenant-driven internal growth. The plan is to grow by working with tenants on space and capital needs, replacing tenants at favorable terms, extending or modifying leases prior to expiration, and delivering strong property management to encourage renewals, expansions, and relocations.
• Janus Living IPO. Healthpeak intends to complete the proposed Janus Living IPO in the first half of 2026 by contributing its 34-community senior housing portfolio and retaining a substantial majority ownership interest while serving as external manager.

The Janus transaction is the most concrete near-term catalyst: it would spin much of the senior housing operating exposure into a separate vehicle, possibly sharpening Healthpeak’s valuation around outpatient medical and lab assets. In January 2026, the company also acquired the remaining 46.5% interest in its SWF SH JV, bringing ownership of those 19 senior housing properties to 100%. Whether that positions Healthpeak for a cleaner contribution into Janus or simply increases exposure to senior housing operating cash flows depends on how the IPO terms and timing settle.

Macro & geopolitical exposure

Because DOC is a healthcare REIT, its macro exposures flow through the real estate and healthcare channels simultaneously. The most direct sensitivity is to interest rates and the cost of capital. Higher rates increase cap rates, reduce asset valuations, and raise the cost of refinancing the debt load. Healthpeak’s stated preference for long-term fixed-rate debt with staggered maturities is a direct response to this risk, not an accident of structure.

On the operational side, outpatient medical buildings rely on hospital-system credit and patient volumes, while reimbursement policy — Medicare, Medicaid, and broader federal and state healthcare regulation — can indirectly affect tenant stability. The lab/life science portfolio is tied to biotech and pharmaceutical R&D cycles, venture-capital funding availability, and geographic demand in the three coastal metros where it is concentrated. Senior housing is exposed to demographics (aging population), labor costs, and local occupancy trends. Commodity and supply-chain risks matter mainly through construction costs for development and redevelopment projects, not through raw-material input pricing the way they would for an industrial manufacturer.

Recent developments

Recent headlines do not point to a single, company-shifting event; they show normal institutional position changes and analyst commentary. On September 17, 2026, defenseworld.net reported that NewEdge Advisors LLC acquired 27,508 shares. A day earlier, on September 16, 2026, seekingalpha.com ran a note headlined “Healthpeak Properties: Buy Reaffirmed As Outpatient And Senior Portfolio Shows Proven Performance.” Also on Seeking Alpha, a September 9, 2026 article included Healthpeak in a broader list titled “Buy 5 S&P500 IDEAL 'Safer' September Dividend Dogs.” Institutional selling appeared as well: defenseworld.net reported on September 8, 2026 that HSBC Holdings PLC reduced its position in the company. Net-net, the flow is mixed and reads like ordinary portfolio rebalancing by active managers around the September dividend window, not a coordinated directional signal.

Earnings behavior & post-earnings drift

The earnings record for Healthpeak is a useful case study in why “beat” does not always mean “rally,” especially for REITs where the market’s real expectation can differ from the published consensus.

Over the last 8 reported quarters, DOC has beaten 4 times, producing a 50% beat rate. The average earnings surprise across those quarters is 18.2%, and the average 5-day price move after earnings is +2.24%, classified as an “up” drift. But the headline average masks a messy pattern: even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise.

The last four quarters make the disconnect clear.

• August 4, 2026: EPS of $0.08 beat the $0.02815 estimate by 184.2%. The stock rose 0.79% the next session but then fell 5.13% over the next five days — a beat followed by negative drift.
• May 5, 2026: EPS of $0.28 crushed the $0.05276 estimate by 430.7%. The stock surged 18.11% the next day and extended that to +19.81% over five days — an extreme positive example.
• February 2, 2026: EPS of $0.16 missed the $0.45 estimate by 64.4%. The stock dipped 2.78% the next day and drifted only slightly lower at −0.47% over five days.
• October 23, 2025: EPS of −$0.17 missed the $0.06 estimate by 383.3%. The stock actually rose 1.19% the next day before falling 5.23% over the following week.

That variability is the key takeaway. Two huge beats produced very different follow-throughs: one was sold into within days, the other produced a multi-week move. Meanwhile, the two misses also produced inconsistent outcomes. Healthpeak reports next on October 22, 2026, after the close, with the consensus EPS estimate at $0.05355. Traders watching this name should treat the published bottom-line estimate as only one input; FFO, same-store NOI, lab leasing spreads, and any Janus Living IPO update are likely to drive price at least as much as the EPS surprise itself.

For a deeper dive into the complete buy/hold/sell landscape, valuation models, and forward FFO projections from institutional analysts, see the full institutional verdict on the ticker page.